Axsome Therapeutics (AXSM) Competitors $98.68 +0.49 (+0.50%) (As of 11/22/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends AXSM vs. GBT, CORT, RARX, AIMT, HRMY, BGNE, UTHR, VTRS, RPRX, and SMMTShould you be buying Axsome Therapeutics stock or one of its competitors? The main competitors of Axsome Therapeutics include Global Blood Therapeutics (GBT), Corcept Therapeutics (CORT), Ra Pharmaceuticals (RARX), Aimmune Therapeutics (AIMT), Harmony Biosciences (HRMY), BeiGene (BGNE), United Therapeutics (UTHR), Viatris (VTRS), Royalty Pharma (RPRX), and Summit Therapeutics (SMMT). Axsome Therapeutics vs. Global Blood Therapeutics Corcept Therapeutics Ra Pharmaceuticals Aimmune Therapeutics Harmony Biosciences BeiGene United Therapeutics Viatris Royalty Pharma Summit Therapeutics Global Blood Therapeutics (NASDAQ:GBT) and Axsome Therapeutics (NASDAQ:AXSM) are both mid-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, community ranking, earnings, dividends, media sentiment, risk, valuation, institutional ownership and analyst recommendations. Which has higher earnings and valuation, GBT or AXSM? Axsome Therapeutics has higher revenue and earnings than Global Blood Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Global Blood Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGlobal Blood Therapeutics$194.75M23.73-$303.09M-$5.01-13.67Axsome Therapeutics$338.46M14.13-$239.24M-$6.53-15.11 Does the MarketBeat Community favor GBT or AXSM? Global Blood Therapeutics received 119 more outperform votes than Axsome Therapeutics when rated by MarketBeat users. However, 69.00% of users gave Axsome Therapeutics an outperform vote while only 64.90% of users gave Global Blood Therapeutics an outperform vote. CompanyUnderperformOutperformGlobal Blood TherapeuticsOutperform Votes56264.90% Underperform Votes30435.10% Axsome TherapeuticsOutperform Votes44369.00% Underperform Votes19931.00% Do analysts prefer GBT or AXSM? Axsome Therapeutics has a consensus target price of $124.93, indicating a potential upside of 26.60%. Given Axsome Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Axsome Therapeutics is more favorable than Global Blood Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Global Blood Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Axsome Therapeutics 0 Sell rating(s) 0 Hold rating(s) 14 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders and institutionals hold more shares of GBT or AXSM? 81.5% of Axsome Therapeutics shares are held by institutional investors. 4.9% of Global Blood Therapeutics shares are held by insiders. Comparatively, 22.4% of Axsome Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Does the media prefer GBT or AXSM? In the previous week, Axsome Therapeutics had 12 more articles in the media than Global Blood Therapeutics. MarketBeat recorded 12 mentions for Axsome Therapeutics and 0 mentions for Global Blood Therapeutics. Global Blood Therapeutics' average media sentiment score of 0.52 beat Axsome Therapeutics' score of 0.30 indicating that Global Blood Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Global Blood Therapeutics Positive Axsome Therapeutics Neutral Is GBT or AXSM more profitable? Axsome Therapeutics has a net margin of -91.87% compared to Global Blood Therapeutics' net margin of -137.30%. Axsome Therapeutics' return on equity of -158.36% beat Global Blood Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Global Blood Therapeutics-137.30% -170.37% -39.24% Axsome Therapeutics -91.87%-158.36%-37.46% Which has more volatility and risk, GBT or AXSM? Global Blood Therapeutics has a beta of 0.45, meaning that its stock price is 55% less volatile than the S&P 500. Comparatively, Axsome Therapeutics has a beta of 1.26, meaning that its stock price is 26% more volatile than the S&P 500. SummaryAxsome Therapeutics beats Global Blood Therapeutics on 13 of the 18 factors compared between the two stocks. Ad DTIDownload Our Tesla Ebook For FreeLike many of you, we here at the TradingPub are bullish on Tesla long term. We believe the company will continue to be a leader in technology, EVs and A.I. We also believe it’s share price will be rewarded in a big way… In fact, our #1 Tesla expert just published a brand new Ebook regarding Tesla’s future, and we’d like to send it to you at no cost.To claim your copy free of charge simply follow this link. Get Axsome Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AXSM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AXSM vs. The Competition Export to ExcelMetricAxsome TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.78B$6.63B$5.20B$8.83BDividend YieldN/A8.11%5.06%4.09%P/E Ratio-15.1110.49112.7217.51Price / Sales14.13368.691,242.97159.41Price / CashN/A52.5939.8636.27Price / Book51.4010.367.056.49Net Income-$239.24M$152.98M$118.72M$225.45M7 Day Performance5.91%4.60%2.20%3.61%1 Month Performance6.80%-7.69%-3.08%3.45%1 Year Performance64.19%33.50%33.70%29.16% Axsome Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AXSMAxsome Therapeutics4.6105 of 5 stars$98.68+0.5%$124.93+26.6%+64.2%$4.78B$338.46M-15.11589Analyst UpgradeGBTGlobal Blood TherapeuticsN/A$68.49flatN/A+0.0%$4.62B$194.75M-13.67457News CoverageCORTCorcept Therapeutics4.7596 of 5 stars$55.91-0.3%$65.25+16.7%+127.1%$5.88B$628.56M44.37300Analyst RevisionPositive NewsRARXRa PharmaceuticalsN/A$47.99flatN/A+0.0%$2.27B$3M-20.7772AIMTAimmune TherapeuticsN/A$34.49flatN/AN/A$2.26BN/A-8.69228HRMYHarmony Biosciences4.8459 of 5 stars$33.23+1.3%$47.00+41.4%+19.5%$1.90B$582.02M15.64200BGNEBeiGene3.1896 of 5 stars$194.56+0.2%$247.07+27.0%+4.2%$18.92B$3.32B-23.6110,600Analyst DowngradeUTHRUnited Therapeutics4.5326 of 5 stars$367.36+0.8%$370.86+1.0%+61.8%$16.27B$2.76B16.131,168Insider TradeAnalyst RevisionPositive NewsVTRSViatris1.4394 of 5 stars$13.26+0.9%$13.33+0.6%+42.7%$15.82B$15.43B-17.9138,000News CoverageRPRXRoyalty Pharma4.779 of 5 stars$26.41+0.7%$41.67+57.8%-2.8%$15.56B$2.36B13.6980SMMTSummit Therapeutics1.8568 of 5 stars$18.42-1.1%$34.75+88.7%+874.4%$13.58B$700,000.00-65.78105 Related Companies and Tools Related Companies GBT Alternatives CORT Alternatives RARX Alternatives AIMT Alternatives HRMY Alternatives BGNE Alternatives UTHR Alternatives VTRS Alternatives RPRX Alternatives SMMT Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:AXSM) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Axsome Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Axsome Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AXSM Stock Alerts